A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)

A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)

10.1038/s41408-021-00544-x

Saved in:

書目詳細資料
Main Authors:	Chen, Yunxin, Gopalakrishnan, Sathish Kumar, Ooi, Melissa, Sultana, Rehena, Lim, Li Hui, Grigoropoulos, Nicholas, Ong, Shin Yeu, Xu, Mingge, Chng, Wee Joo, Goh, Yeow Tee, Nagarajan, Chandramouli
其他作者:	MEDICINE
格式:	Letter
語言:	English
出版:	SPRINGERNATURE 2021
主題:	Science & Technology Life Sciences & Biomedicine Oncology Hematology MULTIPLE-MYELOMA LENALIDOMIDE
在線閱讀:	https://scholarbank.nus.edu.sg/handle/10635/207736
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!
機構:	National University of Singapore
語言:	English

相似書籍

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
由: Moreau, P, et al.
出版: (2022)

Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network
由: Soekojo, Cinnie Yentia, et al.
出版: (2022)

The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): A joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network
由: Tan, D., et al.
出版: (2016)

ELUCIDATING THE ROLE OF ADAR1 IN REGULATING IMMUNOTHERAPEUTIC RESPONSE IN MULTIPLE MYELOMA
由: KOH MUN YEE
出版: (2023)

Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
由: Chng, W-J, et al.
出版: (2022)

Impact of ixazomib-lenalidomide-dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging-markets subgroup of the TOURMALINE-MM1 trial.
由: Spencer, Andrew, et al.
出版: (2023)

A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma
由: Chng, WJ, et al.
出版: (2023)

Thrombotic microangiopathy during carfilzomib use: case series in Singapore
由: Chen, Y, et al.
出版: (2020)

The impact of frontline risk-adapted strategy on the overall survival of patients with newly diagnosed multiple myeloma: An analysis of the Singapore multiple myeloma study group
由: Tan, D., et al.
出版: (2016)

Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial
由: Dimopoulos, Meletios A, et al.
出版: (2022)

Investigating status of tumorigenic barriers in monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM)
由: ZAHRA KABIRI
出版: (2010)

Carfilzomib and Dexamethasone vs Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma: Results of the Phase 3 Study ENDEAVOR (NCT01568866) According to Age Subgroup
由: Heinz Ludwig, et al.
出版: (2018)

A study on the correlation of the compressive strength between 75x150mm, 100x200mm, 125x250mm and 150x300mm concrete cylinder specimens
由: Calderon, Quintin Kristoffer L., et al.
出版: (2008)

Natural history and prognostic factors at first relapse in multiple myeloma
由: Wang, C., et al.
出版: (2021)

Carfilzomib-Dexamethasone vs Subcutaneous or Intravenous Bortezomib in Relapsed or Refractory Multiple Myeloma: Secondary Analysis of Phase 3 ENDEAVOR Study
由: Hartmut Goldschmidt, et al.
出版: (2018)

SGH-NTU collaboration
由: NTU-SGH Annual Biomedical Engineering Symposia
出版: (2008)

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
由: Davies, FE, et al.
出版: (2023)

Centrosomes and myeloma; aneuploidy and proliferation
由: Chng, W.J., et al.
出版: (2016)

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
由: Davies, FE, et al.
出版: (2023)

Extramedullary plasmacytoma of the orbit as initial presentation of multiple myeloma
由: Razak, R.A., et al.
出版: (2016)

Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study
由: Gupta, N, et al.
出版: (2020)

Analisis sikap mahasiswa MM-UGM terhadap proses belajar-mengajar pada program studi MM-UGM
由: , SUPRIYANTO, Y, et al.
出版: (1996)

Multimedia on heroines of the 1896 revolution (MM-Heroines)
由: Co, Wendy U., et al.
出版: (1998)

Mm-wave CMOS phase-locked loops
由: Yi, Xiang
出版: (2014)

Clinical and biological implications of MYC activation: A common difference between MGUS and newly diagnosed multiple myeloma
由: Chng, W.-J., et al.
出版: (2014)

CHARACTERISING THE METABOLIC PHENOTYPE OF C-MAF OVEREXPRESSION IN MULTIPLE MYELOMA
由: LIM SZE LYNN JULIA
出版: (2024)

Multiple Myeloma-Associated Light Chain Amyloidosis and a Proposed Approach to Monoclonal Immunoglobulin-Associated Renal Disease
由: Zi Yun Chang, et al.
出版: (2020)

PEMBUATAN ALAT DAN PENGUJIAN PERMEABILITAS CAMPURAN PASIR SUNGAI DAN SEMEN DENGAN MESH +0.425 mm/- 0.6 mm
由: , ROBERTO SEMBERSI BERMANA, et al.
出版: (2014)

QM-MM investigation on chorismate synthase enzyme role
由: Lawan,N.
出版: (2015)

Interpersonal distance tracking with mmWave radar and IMUs
由: Dai, Yimin
出版: (2023)

Interpersonal distance tracking with mmWave radar and IMUs
由: Dai, Yimin, et al.
出版: (2023)

Broadband power amplifier design at mm wave band
由: Luan, Zixuan
出版: (2024)

Piezoelectric ultrasonic micromotor with 1.5 mm diameter
由: Dong, S., et al.
出版: (2014)

CONCEPTUAL DESIGN OF BALLISTIC ROCKET WITH 325 MM DIAMETER
由: FARRAZ AL FARIZI, MUHAMMAD

DESAIN KONSEPTUAL ROKET BALISTIK DIAMETER 325 MM
由: Farraz Al Farizi, Muhammad

PERANCANGAN JALAN KAWASAN INDUSTRI CIBITUNG MM2100
由: PUTRISARI (NIM: 15014109), MANUELA

Structural studies of the novel virulence factors BswR and SghA/SghR involved in pathogen virulence regulation
由: Ye, Fuzhou
出版: (2015)

UJI EKSPERIMENTAL ORIFICE MULTI LUBANG PADA SALURAN BERDIAMETER 50 MM (EXPERIMENTAL INVESTIGATION OF MULTI-HOLES ORIFICE IN 50 MM DIAMETER PIPE)
由: Waluyo, Joko, et al.
出版: (2013)

Attenuation of STAT3 signaling cascade by daidzin can enhance the apoptotic potential of bortezomib against multiple myeloma
由: Yang, M.H., et al.
出版: (2021)

Qualitative study of factors affecting patient, caregiver and physician preferences for treatment of myeloma and indolent lymphoma
由: Jen, W.-Y., et al.
出版: (2021)